Customers

On September 1, 2020, the United States Bankruptcy Court for the District of Delaware approved the sale of Akorn’s business to our existing lenders. This critical milestone allows Akorn to move beyond the Chapter 11 process under new ownership. We are working to finalize customary closing obligations and anticipate the sale will be completed in the next few weeks.

As has been the case throughout the Chapter 11 process, Akorn will continue normal operations and meet commitments to our stakeholders, including our customers. We look forward to emerging as a more vibrant company, even better positioned to improve patients’ lives through the quality, availability and affordability of our products.

To Our Valued Customers,

As we shared earlier this year, Akorn has been working to execute a sale process that positions our business for long-term success. On May 20, 2020, we took decisive action to achieve this goal – Akorn filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code and will use the process and legal protections provided by Chapter 11 to execute the sale of our business.

Operating Our Business and Meeting Obligations to Customers

Now and throughout the Chapter 11 process, we expect to operate our business as usual, meeting our go-forward commitments to our associates, customers, partners and regulators. Our relationship with you will not be impacted by this announcement. Nothing about this announcement affects our ability to develop, manufacture and deliver our products.

We know that you and the patients you serve depend on the products Akorn provides, and we have taken all of the necessary steps to ensure we can uphold our commitments to you throughout this process. All of our contractual rebate programs and other contractual obligations are continuing as usual.

Our Sale Process and Next Steps

Following a thorough marketing and negotiation process, we announced a purchase agreement with certain of our existing lenders whereby they will serve as the foundational bidder in our court-supervised sale process. Briefly, the next step in this process is to collect any additional bids from buyers other than our existing lenders. If any bids exceed the value of our existing lenders’ bid, the “highest and best” bid will be chosen as the winning bid to be reviewed and approved by the Court. We will then work toward emergence from Chapter 11 under a new ownership structure, which we are hoping to complete in the third quarter of 2020.

More Information

If you have any questions, please feel free to reach out directly to your normal contact. We are committed to keeping customers informed throughout this process and will be providing updates as we are able.

Thank you for your support throughout our sale process and these challenging times. We are confident that this decisive action will allow us to be an even stronger partner for you in the future, and we look forward to working together as we emerge from this process even better positioned to improve patients’ lives.

Warm regards,

Doug Boothe, CEO

Frequently Asked Questions

  1. When Akorn emerges under new ownership, will the Company’s portfolio of products change? How will we know that the products our patients rely on will still be available?

    Nothing about Akorn’s business will change as a result of the sale completion. We will continue developing, manufacturing and delivering the products that you and the patients you serve rely on.

  2. Will my point of contact on the Akorn sales team change?

    No, your point of contact on the Akorn sales team will not change. Our business will continue as usual, and we look forward to being an even stronger partner for you in the future as we work together to improve patients’ lives.

  3. How will customers be kept informed throughout this process? Where can we go if we have additional questions?

    Akorn is fully committed to keeping you informed throughout this process. Should you have any questions, please direct them to your usual company contact.

Contacts

Media Contact
Rachel Chesley / Sarah Rosselet
[email protected]

Investor Contact
[email protected]